|Healthcare (VVUS, LXRX, ENZN, ONCY, OPTR)|
|By Staff and Wire Reports|
|Monday, 17 December 2012 14:49|
Republican House Speaker John Boehner edged closer to President Barack Obama's position as they try to avoid the automatic tax hikes and spending cuts that would take place in the new year if no deal is reached. Following are the notable mover at mid day on Monday:
Lexicon Pharmaceuticals, Inc.(NASDAQ:LXRX) shares climbed 8.29% to $2.03 in the early hour. The company said it has received a Fast Track status from the U.S. Food and Drug Administration for the development of LX1033. LX1033 is an oral drug candidate for diarrhea-predominant irritable bowel syndrome, or IBS-d, and is currently being evaluated in a Phase 2 clinical trial. The Phase 2 trial is a randomized, double-blind study designed to ensure safety and efficacy of LX1033 versus placebo in approximately 360 patients. The results are expected to come out in the first-half of 2013.
Enzon Pharmaceuticals, Inc.(NASDAQ:ENZN) stock increased 3.94% to $4.75. The company said its Board of Directors have retained Lazard to act as its financial advisor regarding a review of the possible sale or disposition of corporate assets, or a sale of the company. Enzon will suspend any ongoing clinical developments so as to conserve capital and maximize value returned to shareholders.
Oncolytics Biotech, Inc. (USA)(NASDAQ:ONCY) stock increased 15.16% to $3.57. The company announced initial positive top line data from the first endpoint in its double-blinded randomized Phase III clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naïve head and neck cancers (REO 018). The endpoint examines initial percentage tumour changes between the pre-treatment and first post-treatment scans (typically performed at six weeks post-first treatment) of all patients enrolled in the study.
VIVUS, Inc.(NASDAQ:VVUS) stock increased 9.93% to $12.62. The company, last month, announced that a study published in the journal SLEEP (2012; 35(11):1529-1539) found that patients with moderate to severe obstructive sleep apnea (OSA) taking phentermine and topiramate extended-release capsules achieved significant improvements in key measures of OSA and cardiovascular risk factors along with weight loss during the 28-week trial. OSA is a chronic and potentially serious sleep disorder in which breathing is abnormally shallow ("hypopnea") or stops altogether ("apnea") for at least 10 seconds.
Optimer Pharmaceuticals, Inc.(NASDAQ:OPTR) shares gained 8.44% to $9.89. The company announced that the first patient has been dosed in its DEFLECT-1, Phase 3b clinical trial of DIFICID (fidaxomicin) tablets for the prevention of Clostridium difficile-associated diarrhea (CDAD) in patients undergoing hematopoietic stem cell transplant (HSCT), often referred to as bone marrow transplantation. CDAD can be a serious complication of HSCT.